Romiplostim shows promise in AA[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag].
Most Relevant Research
In our exploration of how protein treatments can improve anemia, we focused on the impact of romiplostim, a thrombopoietin receptor agonist, on patients suffering from aplastic anemia (AA) who were either refractory to or intolerant of eltrombopag (EPAG). We studied a group of 18 patients, most of whom had severe AA, who transitioned from EPAG to romiplostim for at least three months.
Remarkably, 72% of these patients responded positively to romiplostim, with many showing improvement in their blood cell counts within the first three months. Of these, half demonstrated a trilineage response, meaning their blood counts improved across multiple cell types. However, we noticed that those who initiated romiplostim a significant time after their initial AA diagnosis tended to struggle to respond effectively.
In instances where treatment with romiplostim was interrupted, we observed that some patients relapsed into thrombocytopenia, suggesting that romiplostim plays a critical role in maintaining blood counts. Overall, our findings indicate that romiplostim can be a valuable option for patients who do not benefit from other treatments, bringing renewed hope in the management of this challenging condition.